Tumor Immunology and Immunotherapy (TII)
Tumor Immunology and Immunotherapy (TII)
批准号:
9750163
负责人:
Xuefang Cao
金额:
$4.88万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Antitumor ResponseCancer BurdenCancer CenterCancer Center Support GrantCellsClinicalCollaborationsDevelopmentDiseaseDisease ProgressionFundingFunding AgencyGoalsImmuneImmunosuppressionInfectionInflammationInflammatory ResponseInstitutionInterdisciplinary StudyKnowledgeMalignant - descriptorMalignant NeoplasmsMarylandMentorsMonitorNursing FacultyPeer ReviewPreventive treatmentPublicationsPublishingResearchResearch PersonnelRoleSchoolsSignal TransductionSourceTranslatingTreatment ProtocolsTumor EscapeTumor ImmunityUniversitiesWorkbasecancer cellcancer immunotherapycell growthcollegedesignfaculty supportfallsimmunoregulationinnovationmemberneoplasm immunotherapynovel diagnosticsnovel therapeuticspreventprogramstumor immunology
中文摘要
18.0摘要:肿瘤免疫学和免疫治疗计划
UMCCC肿瘤免疫学和免疫治疗(TII)计划的总体目标是开发
并实施基于免疫的策略,以预防、治疗和/或监测恶性疾病和疾病
进展为了实现这一目标,该计划侧重于三个具体目标:主题1:基于细胞的癌症
免疫疗法-引发能够减少或防止恶性细胞生长主动肿瘤免疫;
主题2:抑制免疫抑制-制定克服肿瘤免疫逃避的策略;
主题三:癌症与炎症-阐明感染和炎症反应在癌症中的作用
发展这项工作的成功实施是由临床医生之间的强有力的互动促进
基础研究人员。方案研究和指导战略旨在促进
初级研究和临床教师的项目内互动和指导。
TII计划有60名成员,代表17个学术部门和5所学校/学院,
马里兰州大学。该计划的成员进行以癌症为重点的研究,获得410万美元
年度资金总额,包括来自NCI的60万美元和来自其他同行评审来源的260万美元。在
此外,TII方案成员每年从非同行审查的资金来源获得90万美元。
2010年1月至2014年12月,TII成员撰写了366篇与癌症相关的出版物,其中
21%来自项目内合作,22%来自项目间合作。
大约52%的出版物代表与外部研究人员的合作。研究
TII教师的努力得到了FCSS,BSS和PBSS的广泛使用的支持。
英文摘要
18.0 Abstract: Tumor Immunology and Immunotherapy Program
The overarching goal of the Tumor Immunology and Immunotherapy (TII) Program of UMGCC is to develop
and implement immune-based strategies to prevent, treat, and/or monitor malignant diseases and disease
progression. To achieve this goal, the program focuses on three specific aims: Theme 1: Cell-based cancer
immunotherapies—elicit active tumor immunity capable of reducing or preventing malignant cell growth;
Theme 2: Inhibiting immunosuppression—develop strategies to overcome tumor immune evasion; and
Theme 3: Cancer and inflammation—elucidate the roles for infection and inflammatory responses in cancer
development. The successful implementation of this work is facilitated by strong interactions between clinicians
and basic researchers. Program research and mentoring strategies are designed to promote inter- and
intraprogrammatic interaction and mentoring of junior research and clinical faculty.
The TII program has 60 members representing 17 academic departments and 5 schools/colleges of the
University of Maryland. Members of the program conduct cancer-focused research that receives $4.1 million
total annual funding, including $0.6 million from NCI and $2.6 million from other peer-reviewed sources. In
addition, TII Program members receive $0.9 million annually from non-peer-reviewed funding sources.
Between January 2010 and December 2014, TII members authored 366 cancer-related publications, of which
21 percent resulted from intraprogrammatic and 22 percent from interprogrammatic collaborations.
Approximately 52 percent of the publications represent collaborations with external investigators. Research
efforts by TII faculty are supported by extensive use of the FCSS, BSS, and PBSS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Beta-2 adrenergic signaling in immune homeostasis and reconstitution
-
批准号:10610471
-
项目类别:
-
资助金额:$76.6万
-
财政年份:2022
-
负责人:Xuefang Cao
-
依托单位:
CD27/CD70 mediated negative regulation of inflammatory T cell responses
-
批准号:10226021
-
项目类别:
-
资助金额:$58.61万
-
财政年份:2018
-
负责人:Xuefang Cao
-
依托单位:
CD27/CD70 mediated negative regulation of inflammatory T cell responses
-
批准号:9523419
-
项目类别:
-
资助金额:$58.61万
-
财政年份:2018
-
负责人:Xuefang Cao
-
依托单位:
Targeting Granzyme B to Separate GVH from GVL Responses
-
批准号:9614558
-
项目类别:
-
资助金额:$24.13万
-
财政年份:2017
-
负责人:Xuefang Cao
-
依托单位:
Targeting Granzyme B to Separate GVH from GVL Responses
-
批准号:9764283
-
项目类别:
-
资助金额:$34.28万
-
财政年份:2017
-
负责人:Xuefang Cao
-
依托单位:
Targeting Beta-Adrenergic Signaling to Control GVH and GVL Responses
-
批准号:9178850
-
项目类别:
-
资助金额:$24.59万
-
财政年份:2016
-
负责人:Xuefang Cao
-
依托单位:
Targeting Beta-Adrenergic Signaling to Control GVH and GVL Responses
-
批准号:9315583
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2016
-
负责人:Xuefang Cao
-
依托单位:
Targeting Granzyme B to Separate GVH from GVL Responses
-
批准号:8888555
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2015
-
负责人:Xuefang Cao
-
依托单位:
Tumor Immunology and Immunotherapy Program
-
批准号:10267045
-
项目类别:
-
资助金额:$5.1万
-
财政年份:2008
-
负责人:Xuefang Cao
-
依托单位:
海外基金